Nabriva Therapeutics AG operates as a biopharmaceutical company that engages in the discovery and development of antibiotics for use in community and hospital infections. The company focuses on antibiotic classes, such as pleuromutilins designed for oral and topical application; and injectable broad-spectrum anti-MRSA cephalosporins
